Navigation Links
Studies Presented at AACR Annual Meeting Highlight Multiple Immunomodulatory Mechanisms of Peregrine's PS-Targeting Antibodies
Date:4/21/2009

tatements regarding Peregrine Pharmaceuticals' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to the risk that results from future preclinical studies and clinical trials will not correlate with the results of these preclinical studies, the risk that the fully human antibodies will not provide comparable results in combination with other cancer therapies and the risk that the Company will experience delays in enrolling patients in its existing and planned clinical studies. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2008 and the quarterly report on Form 10-Q for the quarter ended January 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise an
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
2. Alimera Sciences Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
3. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
4. Cardium Reports on Applicability of Corgentin to Stem Cell Therapies: Independent Studies Indicate that Ad5IGF-1 Potentiates Stem Cells to Improve Cardiac Function After Heart Attack
5. Avineuro Pharmaceuticals, Inc. Announces Beginning of Phase I Clinical Studies of AVN-211, Potent Small Molecule for Treatment of Schizophrenia.
6. Studies Show Combination Laser Therapy Effective At Clearing Acne, Reducing Oil Production
7. Prescient Medical Achieves Milestones in Clinical Studies of vProtect(TM) Luminal Shield
8. Intellect Neurosciences, Inc. Announces Independent Studies on Copper Binding Properties of its Lead Candidate OXIGON(TM)
9. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
10. Oridion Announces Significant Medical Studies Presented at STA
11. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
(Date:12/24/2014)... HILL, N.C. , Dec. 23, 2014  Medical ... success. As the key link between the medical device ... grow even more in the coming years as the ... According to research by benchmarking firm, ... MSLs can gain an important edge is by harnessing ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) ... Blood Glucose Market" report to their offering. ... market insight focuses on the developments in the self-monitoring ... . Reimbursement analysis and the effects of competitive ... than 73 SMBG meters have been performed, based on ...
Breaking Medicine Technology:New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Role of Medical Science Liaisons Evolving in Medical Device Sector 2US Self-monitoring Blood Glucose Market 2
... ,Since the first system was invented in ... and patient care. During the 1960s, blood gas ... were considered "the most important laboratory test for ... by Dr. John Severinghaus, inventor of the blood ...
... ,Contributing Editor , ,Positive patient identification (ID) is ... few years. Until recently, the costs associated with hardware ... or laboratory. Today there are multiple vendors with devices ... ease. Some systems are better for small facilities, while ...
Cached Medicine Technology:Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 2Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 3Blood Gas Analysis: The Pros and Cons of Point-Of-Care Testing 4Managing Preanalytical Processes for Patient Safety 2Managing Preanalytical Processes for Patient Safety 3Managing Preanalytical Processes for Patient Safety 4
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... December 26, 2014 “Every three months the ... changes. A-line sweetheart evening dress will be one of the ... manager of Yunx.co.uk says. Today, the company releases 26 A-line ... up to 80% off. , “We are trying our ... style with our latest designs. Along with affordable prices, we ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... December 25, 2014 Recently, BellasDress ... on all its wedding dresses. BellasDress has chosen their ... for gift choices for the holiday season. , ... pick suitable wedding gowns here at discount prices. The ... experience at its website. , “All our ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... 22 /PRNewswire-Asia-FirstCall/ -- Tianyin,Pharmaceutical Co., Inc., (NYSE AMEX: ... Chinese medicine ("TCM") based in Chengdu, China, today,announced that ... when, according,to a preliminary list of additions posted on ... ("Russell") reconstitutes its,comprehensive set of U.S. and global equity ...
... 22 DIA 45th Annual Meeting -- , , News ... In a new report, IDC Health Insights ... healthcare and life science markets, ranked Oracle as the number one vendor ... The Life Science Software Top 10 identifies the 10 leading ...
... VNA,s Hospice of ... ... are the adjectives Hospice of Philadelphia considered when it developed its new free-standing inpatient hospice ... not always possible. Typically, patients requiring acute care must go to a hospital. ...
... , SAN DIEGO, June 22 /PRNewswire-FirstCall/ -- BioMed Realty ... of a new $18 million loan secured by the company,s 9865 ... of 9865 Towne Centre Drive, a state-of-the-art laboratory and office facility, ... has since received LEED(R) Silver certification for Core and Shell from ...
... June 22 United Spinal Association,s ( www.UnitedSpinal.org ) ... region,s premiere lifestyle-enhancing Expo designed to promote active living and independence ... The Independence Expo will be held on Friday, August 7th and ... in Orlando, FL. , , Pre-register at ...
... TAIPEI, Taiwan, June 22 /PRNewswire-Asia/ -- ... announced the signing of a Memorandum of,Understanding (MOU) ... Center (STPI), a non-profit organization under the National,Applied ... provide,direction and support for Taiwan,s Science & Technology ...
Cached Medicine News:Health News:Tianyin Pharmaceutical Co., Inc. Set to Join Russell Microcap(R) Index 2Health News:Tianyin Pharmaceutical Co., Inc. Set to Join Russell Microcap(R) Index 3Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 2Health News:Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry 3Health News:Unique Facility Designed for the Comfort of Hospice Patients and Their Families 2Health News:Unique Facility Designed for the Comfort of Hospice Patients and Their Families 3Health News:BioMed Realty Trust Closes New $18 Million Secured Loan 2Health News:BioMed Realty Trust Closes New $18 Million Secured Loan 3Health News:United Spinal Association's 2009 Independence Expo Aug. 7th-8th In Orlando: Improving Life for the Disabled and the Aging 2Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 2Health News:Taiwan's Science & Technology Policy Research and Information Center (STPI) and Thomson Reuters Sign MOU of Collaboration to Support Science & Technology Development 3
... lightweight self-adhesive insulin pod that you fill with ... up to three days and then replace. The ... your body through a small flexible tube (called ... into its wireless companion, the Personal Diabetes Manager. ...
The MiniMed Paradigm REAL-Time System is the world's first system to integrate an insulin pump with REAL-Time continuous glucose monitoring, taking diabetes management to a level you just can't achie...
The IR 1000 Insulin Infusion Pump from Animas offers unprecedented safety features, performance, and convenience....
... Radiancys premium product for acne, ... clinical results on a scalable multi-application ... fight against acne, XtremeClear works fast, ... first few treatments. Uncompromising safety in ...
Medicine Products: